波士顿科学会暂停AVANT GUARD试验,因为在未使用药物患者中发现了意想不到的结果. Boston Scientific pauses AVANT GUARD trial over unexpected observations in drug-naive patients.
波士顿科学公司暂时暂停了AVANT GUARD试验的招生,该试验评估其Farapulse脉冲野外移除系统在治疗持续性心房动时的安全性和有效性. Boston Scientific has temporarily paused enrollment in its AVANT GUARD trial, which assesses the safety and effectiveness of its Farapulse Pulsed Field Ablation System for treating persistent atrial fibrillation. 这一决定是由于在以前未经研究的药物新手患者中发生的意外观察结果. This decision follows unexpected observations in drug-naive patients, a group not previously studied. 尽管受到这一挫折,该公司报告第三季度强劲销售额为42.1亿美元,其驱动因素是电生理销售额大幅增加。 Despite this setback, the company reported strong third-quarter sales of $4.21 billion, driven by a significant increase in electrophysiology sales.